News

60 Minutes Australia Pushes Unproven Stem Cells for Cerebral Palsy

A stem cells for cerebral palsy 60 minutes ad.

The 60 Minutes show here in the U.S. has done sobering segments over the years on risky, unproven stem cell clinics, but now there is a new episode of 60 Minutes Australia that is the polar opposite: it mostly made a mess of things with its fluffy coverage of the story of a wonderful little […]

60 Minutes Australia Pushes Unproven Stem Cells for Cerebral Palsy Read More »

Mesoblast gets FDA RMAT; List of 10 total designations so far

Mesoblast-e1514313188176

Australian stem cell biotech Mesoblast announced that it has received regenerative medicine advanced therapy (RMAT) designation from the U.S. FDA. This is very good news for the company and an encouraging development for the field. Interestingly, last month the FDA clarified that there is expanded RMAT designation that can include gene therapies too. At the Meeting

Mesoblast gets FDA RMAT; List of 10 total designations so far Read More »

Stem cells Sunday brunch of good news, fun links, & cool papers

Liao-et-al-Figure-2D

Enjoy! A Sunday brunch for the brain of science news, helpful links, and notable new papers including on stem cells. News and links CBER Director Focuses on Flexibility to Advance Regenerative Medicines Lab-Grown Blood Stem Cells Produced at Last Transplanted stem cells become eggs in sterile mice Maryland fund awards $8.5 million for stem cell research Positively good news from Asterias

Stem cells Sunday brunch of good news, fun links, & cool papers Read More »

Stem Cell News Briefs: Anversa, Japan Regs, Ocata Suit, More

Timothy-J.-Kieffer

It’s been a busy few weeks for the stem cell field. Below are some news briefs on developments. RetractionWatch reports that Piero Anversa is leaving Harvard/Brigham and Women’s Hospital after an investigation and dismissed lawsuit he filed against the institution. All still quiet on the STAP cell front at the same institutions. There’s some more

Stem Cell News Briefs: Anversa, Japan Regs, Ocata Suit, More Read More »

Statins dilemma: heart & cancer benefits, but diabetes risk

statin_drugs

Statins have been hailed as some of the best drugs ever. Given the massive, deadly prevalence of cardiovascular disease, some have even semi-jokingly talked about putting these drugs in the water supply for public health. The growing evidence (e.g. this story) that statins might significantly aid in prevention, delayed progression, or even post-treatment delay of

Statins dilemma: heart & cancer benefits, but diabetes risk Read More »

Stem Cell Tourism and Patient Education

Stem-Cell-Symbol

What is the role of public education and stem cell tourism? What type of education is available to patients, caregivers and the public? Can public education actually change people’s minds such that they won’t undergo an unproven stem cell-based intervention (SCBI)? These are the questions I will discuss here. But first, let’s just give a

Stem Cell Tourism and Patient Education Read More »

StemCells, Inc. Faces Lawsuit With Serious Allegations

stemcellsinc-logo

StemCells, Inc. is one of those stem cell-related biotech companies that we in the field hope will become a big success and help many patients in the future via stem cell technology. There are a lot of obstacles facing such companies. Some are privately held, while others such as StemCells, Inc. are publicly traded (stock

StemCells, Inc. Faces Lawsuit With Serious Allegations Read More »